Epicrispr Biotechnologies

We’re excited to be at World Muscle Society’s #WMS2024 this week to present some of the robust preclinical data on EPI-321, our epigenetic editing candidate for the treatment of #FSHD. Our poster will be available here once the presentation concludes: https://lnkd.in/eFMKkJj5 ? ? #epicrispr #epigeneticediting??

Our Head of Strategy and Operations, Benson Cheng, PhD, will be on-site in Phoenix, AZ, for Alliance for Regenerative Medicine's #CGMesa24. Want to connect? Find him on the conference partnering system and set up a one-on-one meeting.?

There’s still time to schedule one-on-one meetings with our?CEO, Amber Salzman, as she shares exciting updates at?Oppenheimer & Co. Inc.'s?Private Life Sciences Company Showcase on October 1 in New York. Please message us if you are interested in scheduling time to meet!? ? #EpigeneticEditing

#EpigeneticEditing is on ??! And for good reason: It holds the potential to change the expression of genes without changing the underlying DNA. Check out this article from Labiotech.eu featuring Epicrispr Biotechnologies as one of the leading innovators in this space: https://lnkd.in/enqj5ifA #biotechnology #epigenetics

It’s #MuscularDystrophyAwareness Month, an opportunity to shed light on the many types of muscular dystrophy that collectively affect millions of people worldwide. At Epicrispr we’re passionate about delivering a better treatment for facioscapulohumeral muscular dystrophy (FSHD) by leveraging #EpigeneticEditing to address the epigenetic causes of the disease. #CureFSHD #musculardystrophy

Our scientific founder Lei (Stanley) Qi and colleagues recently published an authoritative review of the field of #EpigeneticEditing in Cell Press. The article surveys today’s technologies for targeted epigenetic editing, and describes its next act: as an entirely new modality for the safe treatment of diseases that have few or no options for disease-modifying therapy today. Read in full here: https://lnkd.in/dCQBRHfN

This week we’ll be at the Cold Spring Harbor Laboratory Genome Engineering: CRISPR Frontiers conference to present 3 posters sharing advances in our hypercompact #EpigeneticEditing tools, including proprietary super-small Cas effectors and transcriptional activators. Hope to see you there! #cshlCRISPR24 #CRISPR

Data we presented this spring at #ASGCT24 showed the promise of our lead candidate, EPI-321, to uniquely address the epigenetic root cause?of #FSHD muscular dystrophy. In this interview with CGTLive, our Head of Therapeutics Alexandra Collin de l'Hortet describes the mode of action of EPI-321 and the robust preclinical dataset that supports its potential to have a transformative impact for people with FSHD: https://lnkd.in/e-uufmYv

Epic is looking forward to participating in?Canaccord Genuity Group Inc.'s 44th Annual Growth Conference in Boston next month! Reach out if you would like to schedule time to meet with us. #EpigeneticEditing #biotechnology

This week we will attend the BMO 2024 Genetic Medicines Summit in New York City. Interested in learning more about our leading epigenetic editing platform? Reach out to set up a meeting at [email protected].?BMO Capital Markets